Skip to main content
Premium Trial:

Request an Annual Quote

Mirna miRNA Patent Application Gets USPTO Nod

Premium

Mirna Therapeutics said this week that it has received a notice that the US Patent and Trademark Office has allowed claims within a patent application related to the therapeutic use of microRNA-34a.

According to the company, miR-34a is a potent tumor suppressor, and the patent application describes methods of reducing cancer cell viability by introducing the non-coding RNA into cancerous T cells or lung, prostate, or skin cancer cells.

Mirna is currently developing a miR-34a mimic that it expects to move into phase I testing next year (GSN 1/20/2011).

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.